George Kk Lau

Summary

Affiliation: The Chinese University of Hong Kong

Publications

  1. ncbi request reprint Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
  2. pmc Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study
    George K K Lau
    Clinical Trial Center, LKS Faculty of Medicine, The University of Hong Kong, Alice Ho Miu Ling Nethersole Hospital, Hong Kong SAR, China
    Korean J Hepatol 16:315-20. 2010
  3. ncbi request reprint Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
    George K K Lau
    Division of Gastroenterology and Hepatology, University Department of Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, China
    Gastroenterology 125:1742-9. 2003
  4. ncbi request reprint Treatment of Hepatitis B e Antigen-negative Patients
    Chee Kin Hui
    George K Lau, MD, FRCP Department of Medicine, Room 1838, Block K, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China
    Curr Treat Options Gastroenterol 10:474-82. 2007
  5. doi request reprint HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon
    George K K Lau
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Liver Int 29:125-9. 2009
  6. ncbi request reprint Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation
    George K K Lau
    Division of Gastroenterology and Hepatology, University of Hong Kong, Hong Kong Special Administrative Region, China
    Hepatology 36:702-9. 2002
  7. doi request reprint Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion
    George K K Lau
    Clinical Trial Center, LKS Faculty of Medicine, The University of Hong Kong, Humanity and Health GI and Liver Clinic, Hong Kong, SAR
    Liver Int 30:512-20. 2010
  8. ncbi request reprint Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase
    G K K Lau
    Departments of Medicine and Pathology, Queen Mary Hospital Clinical Trials Centre, The Institute of Molecular Biology, The University of Hong Kong, Hong Kong SAR, China
    J Viral Hepat 9:280-7. 2002
  9. pmc Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies
    George Lau
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Hepatol Int 1:316-25. 2007
  10. pmc Hepatitis B reactivation after chemotherapy: two decades of clinical research
    George K K Lau
    Department of Medicine, The University of Hong Kong, Room 1838, Block K, Queen Mary Hospital, 102 Pokfulum Road, Hong Kong, Hong Kong SAR China
    Hepatol Int 2:152-62. 2008

Detail Information

Publications56

  1. ncbi request reprint Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong SAR, China
    N Engl J Med 352:2682-95. 2005
    ....
  2. pmc Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study
    George K K Lau
    Clinical Trial Center, LKS Faculty of Medicine, The University of Hong Kong, Alice Ho Miu Ling Nethersole Hospital, Hong Kong SAR, China
    Korean J Hepatol 16:315-20. 2010
    ..In a previous pivotal phase III clinical study, 24 weeks treatment with clevudine 30 mg has been shown to profoundly suppress HBV replication and normalize serum alanine aminotransferase level...
  3. ncbi request reprint Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy
    George K K Lau
    Division of Gastroenterology and Hepatology, University Department of Medicine, Queen Mary Hospital, Hong Kong Special Administrative Region, China
    Gastroenterology 125:1742-9. 2003
    ....
  4. ncbi request reprint Treatment of Hepatitis B e Antigen-negative Patients
    Chee Kin Hui
    George K Lau, MD, FRCP Department of Medicine, Room 1838, Block K, The University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China
    Curr Treat Options Gastroenterol 10:474-82. 2007
    ..However, this latter approach can lead to development of viral resistance and long-term safety concerns...
  5. doi request reprint HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon
    George K K Lau
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Liver Int 29:125-9. 2009
    ..Recently, based on long-term follow-up study, the better durability of sustained response further enhances the confidence in the use of PEG-IFN-alpha in chronic HBeAg-positive patients...
  6. ncbi request reprint Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation
    George K K Lau
    Division of Gastroenterology and Hepatology, University of Hong Kong, Hong Kong Special Administrative Region, China
    Hepatology 36:702-9. 2002
    ..09; P =.021). In conclusion, preemptive lamivudine reduced HBV exacerbation. The use of lamivudine with other immunosuppressive regimens to prevent exacerbation of HBV should be further explored...
  7. doi request reprint Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion
    George K K Lau
    Clinical Trial Center, LKS Faculty of Medicine, The University of Hong Kong, Humanity and Health GI and Liver Clinic, Hong Kong, SAR
    Liver Int 30:512-20. 2010
    ..The mechanisms for enhanced HBeAg seroconversion rates with new-generation NAs are also discussed...
  8. ncbi request reprint Thymosin-alpha1 and famciclovir combination therapy activates T-cell response in patients with chronic hepatitis B virus infection in immune-tolerant phase
    G K K Lau
    Departments of Medicine and Pathology, Queen Mary Hospital Clinical Trials Centre, The Institute of Molecular Biology, The University of Hong Kong, Hong Kong SAR, China
    J Viral Hepat 9:280-7. 2002
    ..Hence combination therapy with immunomodulatory agents and nucleoside analogues should be explored...
  9. pmc Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies
    George Lau
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
    Hepatol Int 1:316-25. 2007
    ..This article reviews the current treatments available and suggests a framework for a rational approach to managing the disease...
  10. pmc Hepatitis B reactivation after chemotherapy: two decades of clinical research
    George K K Lau
    Department of Medicine, The University of Hong Kong, Room 1838, Block K, Queen Mary Hospital, 102 Pokfulum Road, Hong Kong, Hong Kong SAR China
    Hepatol Int 2:152-62. 2008
    ..Careful epidemiological study will be needed to clarify the impact of occult hepatitis B infection in patients treated with cytotoxic or immunosuppressive therapy...
  11. doi request reprint 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B
    Chee Kin Hui
    Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    J Hepatol 48:714-20. 2008
    ..To determine the efficacy of adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy in chronic HBV infection...
  12. doi request reprint Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications
    Chee Kin Hui
    Department of Microbiology, The University of Hong Kong, Hong Kong SAR, China
    J Clin Gastroenterol 42:533-8. 2008
    ..Improvement in modified HAI after antiviral therapy has usually been defined as a 2-point reduction in modified HAI score...
  13. ncbi request reprint High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation
    George K K Lau
    Division of Gastroenterology and Hepatology, University Department of Medicine, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, People s Republic of China
    Blood 99:2324-30. 2002
    ..A high HBV DNA level (>10(5) copies/mL) was the most important risk factor for HBV reactivation, and its lowering by administration of nucleoside analogues before transplantation should be considered...
  14. ncbi request reprint Sexual transmission of hepatitis B infection despite the presence of hepatitis B virus immunity in recipients of allogeneic bone marrow transplantation
    Chee Kin Hui
    Division of Gastroenterology and Hepatology, University Department of Medicine, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong, SAR, China
    J Clin Virol 32:173-8. 2005
    ..After hematopoietic cell transplantation (HCT), hepatitis due to hepatitis B virus (HBV) rarely occurred beyond the initial 12 months after transplantation...
  15. ncbi request reprint Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors
    Chee Kin Hui
    Division of Gastroenterology and Hepatology, The University of Hong Kong, China
    Am J Transplant 5:1437-45. 2005
    ..01, adjusted hazards ratio 7.27, 95%CI 1.62-32.58). Our data support the use of prophylactic therapy in preventing HBV-related hepatitis after allogeneic HSCT from HBsAg-positive donor...
  16. ncbi request reprint Hepatitis B reactivation in patients positive for hepatitis B surface antigen undergoing autologous hematopoietic cell transplantation
    Shing Yan Ma
    Division of Hematology, University Department of Medicine, The University of Hong Kong, Hong Kong SAR, People s Republic of China
    Leuk Lymphoma 44:1281-5. 2003
    ..However, the latter approach would need the patient's hepatitis B viral load be monitored at a very close interval and might not be cost-effective...
  17. ncbi request reprint Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China
    Antivir Ther 12:705-18. 2007
    ..The patterns of hepatitis B viral dynamics during different antiviral therapies and the associated changes in HBV-specific T-cell reactivity are not well defined...
  18. ncbi request reprint A long-term follow-up study on hepatitis B surface antigen-positive patients undergoing allogeneic hematopoietic stem cell transplantation
    Chee Kin Hui
    Division of Gastroenterology and Hepatology, The University of Hong Kong, SAR, China
    Blood 106:464-9. 2005
    ..Our study showed that long-term hepatic complications occur in a significant proportion of HBsAg+ patients after HSCT and the incidence of liver cirrhosis is reduced in those with sustained serologic clearance of HBsAg after HSCT...
  19. ncbi request reprint Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection
    Chee Kin Hui
    Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
    J Clin Virol 35:185-92. 2006
    ..946). In conclusion, chronic HCV patients with occult HBV co-infection does not seem to progress more than patients without occult HBV infection. However, more large-scale studies are needed before a definite conclusion can be obtained...
  20. ncbi request reprint Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients
    Chee Kin Hui
    Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong Special Administrative Region SAR, China
    Hepatology 46:690-8. 2007
    ..00 to -0.70 fibrosis units/year, versus median 0.51 fibrosis units/year, range 0 to +2.03 fibrosis units/year, P = 0.02)...
  21. ncbi request reprint Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy
    Chee Kin Hui
    Centre For The Study of Liver Diseases, The University of Hong Kong, Hong Kong SAR, China
    Gastroenterology 131:59-68. 2006
    ..De novo hepatitis B virus (HBV)-related hepatitis after chemotherapy results in high morbidity and mortality. We evaluate the clinical course of de novo HBV-related hepatitis after chemotherapy...
  22. ncbi request reprint Current issues and future directions in treatment
    Chee Kin Hui
    Center for the Study of Liver Diseases, The University of Hong Kong, SAR, China
    Semin Liver Dis 26:192-7. 2006
    ..Further improvement in CHB therapy is limited by a lack of understanding of the host immune characteristics associated with sustained disease remission...
  23. ncbi request reprint Immune system and hepatitis B virus infection
    Chee Kin Hui
    Department of Medicine, The University of Hong Kong, Hong Kong SAR, China
    J Clin Virol 34:S44-8. 2005
    ..Therapeutic strategies aimed at correcting this defective T cell reactivity could represent a complementary approach to the cure of chronic HBV infection...
  24. ncbi request reprint Peginterferon-alpha2a (40 kDa) (Pegasys) for hepatitis B
    Chee Kin Hui
    Department of Medicine, Center for the Study of Liver Diseases, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China
    Expert Rev Anti Infect Ther 3:495-504. 2005
    ....
  25. pmc Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy
    Chee Kin Hui
    Department of Medicine, University of Hong Kong, Hong Kong, SAR, China
    J Clin Microbiol 44:2983-7. 2006
    ..The results of the RealART and Digene Hybrid assays were related (r = 0.94; P < 0.001) and diverged by 2 orders of magnitude. The RealART assay can be used to effectively monitor serum hepatitis B virus DNA levels...
  26. ncbi request reprint Hepatitic graft-versus-host disease after hematopoietic stem cell transplantation: clinicopathologic features and prognostic implication
    Shing Y Ma
    Department of Medicine, Queen Mary Hospital, Hong Kong, China
    Transplantation 77:1252-9. 2004
    ..This study defines the clinicopathologic features and prognostic implications of hepatitic GVHD compared with classic liver GVHD...
  27. ncbi request reprint Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area
    Chee Kin Hui
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Hong Kong SAR, China
    J Hepatol 42:813-9. 2005
    ..The aim of this study is to determine the prevalence of occult HBV in allogeneic hematopoietic stem cell (HSC) transplantation donors...
  28. ncbi request reprint Silver nanoparticles inhibit hepatitis B virus replication
    Lei Lu
    Department of Medicine, The University of Hong Kong, Pokfulam Road, Hong Kong, China
    Antivir Ther 13:253-62. 2008
    ..The aim of the present study was to investigate the effects of silver nanoparticles on hepatitis B virus (HBV)...
  29. ncbi request reprint Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East
    Vincent C C Cheng
    Department of Microbiology, Center for the Study of Liver Disease, University of Hong Kong Medical Center, Queen Mary Hospital, Hong Kong SAR, China
    Semin Liver Dis 23:239-50. 2003
    ..The mechanisms by which transfer of immunity occurs and its potential relationship with grafts from living related donors should be further explored...
  30. ncbi request reprint Macrophage migration inhibitory factor expression correlates with inflammatory changes in human chronic hepatitis B infection
    Hai Ying Zhang
    Department of Medicine, The University of Hong Kong, Hong Kong, SAR, China
    Liver Int 25:571-9. 2005
    ..Macrophage migration inhibitory factor (MIF) has emerged to be a pivotal cytokine in immune-mediated diseases...
  31. ncbi request reprint Serum adiponectin is increased in advancing liver fibrosis and declines with reduction in fibrosis in chronic hepatitis B
    Chee Kin Hui
    Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong SAR, China
    J Hepatol 47:191-202. 2007
    ..We studied the role of adiponectin in 2 chronic hepatitis B (CHB)-patient cohorts...
  32. ncbi request reprint Management of chronic hepatitis B in treatment-experienced patients
    Chee Kin Hui
    Division of Gastroenterology and Hepatology, University Department of Medicine, Queen Mary Hospital, 103 Pokfulam Road, Hong Kong SAR, China
    Gastroenterol Clin North Am 33:601-16, x. 2004
    ....
  33. ncbi request reprint Treatment of immunosuppressed chronic hepatitis B patients
    George K K Lau
    Department of Medicine, The University of Hong Kong, Hong Kong, SAR, China
    Med J Malaysia 60:57-62. 2005
  34. ncbi request reprint Clevudine for the treatment of chronic hepatitis B virus infection
    Chee Kin Hui
    Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China
    Expert Opin Investig Drugs 14:1277-84. 2005
    ..Based on the early results of clevudine, more large-scale human studies with clevudine monotherapy or combination therapy is eagerly awaited...
  35. ncbi request reprint Role of liver biopsy in the management of liver dysfunction after hematopoietic stem-cell transplantation in a hepatitis B virus-prevalent patient population
    Shing Yan Ma
    University Department of Medicine, Queen Mary Hospital, Hong Kong
    Transplantation 76:169-76. 2003
    ..The role of liver biopsy in such cases has not been defined in hepatitis B virus (HBV)-prevalent patients. The impact of liver biopsy in the management of LFT derangement after HSCT in an HBV-prevalent population was examined...
  36. ncbi request reprint A new and sensitive method for the quantification of HBV cccDNA by real-time PCR
    Ming Liang He
    The Institute of Molecular Biology and Open Laboratory of the Institute of Molecular Technology for Drug Discovery and Synthesis, Hong Kong, China
    Biochem Biophys Res Commun 295:1102-7. 2002
    ..Not only is this method rapid, economical, highly sensitive, it can be used to monitor HBV cccDNA in infected human liver biopsies and to guide patients undergoing long-term anti-HBV therapy...
  37. ncbi request reprint Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use
    Kam Chuen Lai
    Departments of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong, China
    N Engl J Med 346:2033-8. 2002
    ..The role of gastric acid suppression in preventing the recurrence of ulcer complications after the eradication of Helicobacter pylori infection in patients taking long-term low-dose aspirin is uncertain...
  38. doi request reprint Therapeutic efficacy of Traditional Chinese Medicine 319 recipe on hepatic fibrosis induced by carbon tetrachloride in rats
    K F Cheung
    Department of Medicine, The University of Hong Kong, HKSAR, China
    J Ethnopharmacol 124:142-50. 2009
    ..TCM 319 recipe is a Chinese Medicine formula which consists of six Chinese herbs. In this study, we investigated the anti-fibrotic efficacy and mechanisms of TCM 319 recipe...
  39. ncbi request reprint Toward the proteomic identification of biomarkers for the prediction of HBV related hepatocellular carcinoma
    Qing Yu He
    Department of Chemistry and Open Laboratory of Chemical Biology, University of Hong Kong, Hong Kong, China
    J Cell Biochem 103:740-52. 2008
    ..Given the fact that SAA is not a specific biomarker, further attempt is being made to identify the other two most discriminatory peaks to realize the possibility of using the predictive model for HCC surveillance and prediction...
  40. ncbi request reprint Serum biomarkers of hepatitis B virus infected liver inflammation: a proteomic study
    Qing Yu He
    Department of Chemistry, University of Hong Kong, Pokfulam, Hong Kong, China
    Proteomics 3:666-74. 2003
    ..These unique phenomena appear specific to HBV infection. A combination simultaneously considering the quantities and isoforms of these proteins could be a useful serum biomarker (or index) for HBV diagnosis and therapy...
  41. doi request reprint Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a
    Patrick Marcellin
    Service d hépatologie and INSERM CRB3, University of Paris, Hopital Beaujon, Clichy, France
    Liver Int 28:477-85. 2008
    ..Pooled data from five studies of peginterferon alpha-2a in patients with chronic HCV infection (CHC) were compared with two studies of the drug in patients with chronic HBV infection (CHB)...
  42. ncbi request reprint Prophylactic lamivudine therapy for hepatitis B patients undergoing immunosuppressive therapy
    George K K Lau
    Blood 100:3054. 2002
  43. ncbi request reprint Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen
    George K K Lau
    Institute of Hepatology, University College London, London, England
    Gastroenterology 122:614-24. 2002
    ..We characterized HBV-specific T-cell responses in chronic hepatitis B surface antigen carriers who received bone marrow from HLA-identical donors with natural immunity to HBV and seroconverted to antibody to hepatitis B surface antigen...
  44. ncbi request reprint Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, INSERM Unité 481 and Centre de Recherches Claude Bernard sur les Hépatites Virales, Hopital Beaujon, Clichy, France
    N Engl J Med 351:1206-17. 2004
    ..As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy associated with the risk of resistance and unknown long-term safety implications...
  45. doi request reprint HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B
    Michael W Fried
    University of North Carolina, Chapel Hill, NC 27599 7584, USA
    Hepatology 47:428-34. 2008
    ..Late responders to peginterferon alfa-2a could also be differentiated from nonresponders by continued decrease in HBeAg values, which were not evident by changes in HBV DNA...
  46. ncbi request reprint Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy
    Chee Kin Hui
    Blood 105:2616-7. 2005
  47. ncbi request reprint A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B
    Patrick Marcellin
    Service d Hepatologie, Hopital Beaujon, Clichy, France
    Hepatology 40:140-8. 2004
    ..The pharmacokinetic profile of clevudine was proportional to the dose. In conclusion, these results demonstrate the tolerability and potent activity of clevudine in HBV-infected patients and support further clinical study...
  48. ncbi request reprint Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs
    Harry L A Janssen
    Hepatology 42:1459; author reply 1459-60. 2005
  49. ncbi request reprint Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance
    Jinlin Hou
    Institute of Hepatology, University College London, London WC1E 6HX, UK
    J Med Virol 79:1055-63. 2007
    ..The optimal duration of interferon-based therapies in chronic hepatitis B may vary between different HBV genotypes...
  50. ncbi request reprint Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine
    Pierre Vandepapeliere
    GlaxoSmithKline Biologicals, 1330 Rixensart, Belgium
    Vaccine 25:8585-97. 2007
    ....
  51. doi request reprint Dynamic programmed death 1 expression by virus-specific CD8 T cells correlates with the outcome of acute hepatitis B
    Zheng Zhang
    Research Center for Biological Therapy, Beijing 302 Hospital, Beijing, China
    Gastroenterology 134:1938-49, 1949.e1-3. 2008
    ....
  52. ncbi request reprint Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update
    Yun Fan Liaw
    Liver Research Unit, Chang Gung Memorial Hospital, Taipei, Taiwan
    Liver Int 25:472-89. 2005
    ..A large amount of new data on the treatment of chronic hepatitis B has become available such that the 2003 consensus statement requires revision and update...
  53. ncbi request reprint Asian-Pacific consensus statement on the management of chronic hepatitis B: an update
    Yun Fan Liaw
    Liver Research Unit, Chang Gung University, Taipei, Taiwan
    J Gastroenterol Hepatol 18:239-45. 2003
  54. ncbi request reprint Does treatment with interferon-based therapy improve the natural history of chronic hepatitis B infection?
    George K K Lau
    J Hepatol 46:6-8. 2007
  55. ncbi request reprint Late-onset pure red blood cell aplasia owing to delayed lymphoid engraftment complicating ABO-mismatched hematopoietic stem cell transplantation
    Wing Y Au
    Transfusion 44:946-7. 2004